Giancarlo Dr Agnelli

Q: What Schools Are Affiliated With Giancarlo Dr Agnelli

Giancarlo Dr Agnelli is affiliated with the following schools: University of Perugia, McMaster University, University of Brescia

Giancarlo Dr Agnelli's AcademicInfluence.com Rankings

Medical

#1283

World Rank

#1606

Historical Rank

Cardiology

#89

World Rank

#90

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Giancarlo Dr Agnelli Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Giancarlo Dr Agnelli's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). (2008) (2897)
Oral rivaroxaban for symptomatic venous thromboembolism. (2010) (2225)
ESC Guidelines on the diagnosis and management of acute pulmonary embolism (2014) (2085)
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (2079)
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. (2014) (1978)
Oral apixaban for the treatment of acute venous thromboembolism. (2013) (1942)
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. (2012) (1713)
Venous thromboembolism (VTE) in Europe (2007) (1348)
Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (2004) (1348)
Apixaban for extended treatment of venous thromboembolism. (2013) (1134)
Fibrinolysis for patients with intermediate-risk pulmonary embolism. (2014) (1108)
Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. (2000) (816)
Prognostic Value of Troponins in Acute Pulmonary Embolism: A Meta-Analysis (2007) (672)
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. (2002) (669)
A Clinical Outcome-Based Prospective Study on Venous Thromboembolism After Cancer Surgery: The @RISTOS Project (2006) (630)
Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary Embolism: A Meta-Analysis of the Randomized Controlled Trials (2004) (597)
Aspirin for preventing the recurrence of venous thromboembolism. (2012) (581)
Critical issues in peripheral arterial disease detection and management: a call to action. (2003) (578)
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. (2009) (563)
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. (2001) (553)
Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. (2003) (542)
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. (2020) (484)
Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. (1998) (483)
Early Hemorrhagic Transformation of Brain Infarction: Rate, Predictive Factors, and Influence on Clinical Outcome: Results of a Prospective Multicenter Study (2008) (414)
Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism (2003) (391)
Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. (2006) (383)
PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. (1992) (356)
Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study (2007) (350)
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. (2008) (336)
Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high‐risk abdominal surgery (2005) (332)
Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials (2011) (328)
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. (2012) (307)
Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. (2005) (301)
A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score (2012) (282)
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. (2011) (282)
Prevention of Venous Thromboembolism in Surgical Patients (2004) (275)
Efficacy and Safety of Anticoagulant Treatment in Acute Cardioembolic Stroke: A Meta-Analysis of Randomized Controlled Trials (2007) (267)
Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. (2015) (259)
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement (2003) (255)
Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. (2007) (243)
Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. (2018) (236)
D-dimer testing as an adjunct to ultrasonography in patients with clinically suspected deep vein thrombosis: prospective cohort study (1998) (235)
Three months vs. one year of oral anticoagulant therapy for idiopathic deep venous thrombosis (2002) (232)
Acute pulmonary embolism. (2010) (232)
Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. (2009) (231)
Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. (2000) (229)
PRODIGE: a randomized placebo‐controlled trial of dalteparin low‐molecular‐weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma (2010) (227)
Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration (2014) (226)
Guidance for the treatment of deep vein thrombosis and pulmonary embolism (2016) (223)
Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? (2002) (213)
Erratum: 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism (European Heart Journal (2014) 35 (3033-73) DOI 10.1093/eurheartj/ehu283) (2015) (210)
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study (2003) (204)
Erratum to: Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention (2011) (200)
Multidetector computed tomography for acute pulmonary embolism: diagnosis and risk stratification in a single test. (2011) (196)
Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing The RAF Study (2015) (195)
Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. (2010) (195)
Risk factors for catheter‐related thrombosis (CRT) in cancer patients: a patient‐level data (IPD) meta‐analysis of clinical trials and prospective studies (2011) (189)
Antithrombotic therapy for venous thromboembolic disease. (1998) (180)
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial (2015) (179)
Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events. (2010) (179)
Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. (2010) (177)
[2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism]. (2014) (174)
Dose-Response Study of Recombinant Factor VIIa/Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement (2001) (172)
Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group. (1994) (172)
Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model (2016) (165)
Thrombolysis vs heparin in the treatment of pulmonary embolism: a clinical outcome-based meta-analysis. (2002) (160)
A Randomised Trial of Subcutaneous Low Molecular Weight Heparin (CY 216) Compared with lntravenous Unfractionated Heparin in the Treatment of Deep Vein Thrombosis (1991) (150)
A Randomized Study on 1-Week Versus 4-Week Prophylaxis for Venous Thromboembolism After Laparoscopic Surgery for Colorectal Cancer (2014) (149)
Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF (2016) (149)
Anticoagulants in heart disease: current status and perspectives. (2007) (143)
A prospective study on cardiovascular events after acute pulmonary embolism. (2005) (142)
Computed tomography to assess risk of death in acute pulmonary embolism: a meta-analysis (2014) (140)
Practice Guidelines (8th Edition) of Chest Physicians Evidence-Based Clinical Thromboembolic Disease: American College Antithrombotic Therapy for Venous (2008) (139)
Long‐term outcomes of patients with cerebral vein thrombosis: a multicenter study (2012) (139)
Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis (2019) (136)
Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent? (2007) (133)
Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). (2007) (132)
Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. (2006) (130)
Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry (2008) (130)
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study (2005) (128)
The Concept of Ischemic Penumbra in Acute Stroke and Therapeutic Opportunities (2009) (128)
Low ankle–brachial index predicts an adverse 1‐year outcome after acute coronary and cerebrovascular events (2006) (123)
Venous thrombosis (2015) (122)
Clinical features and short term outcomes of patients with acute pulmonary embolism. The Italian Pulmonary Embolism Registry (IPER). (2012) (118)
Early seizures in patients with acute stroke: Frequency, predictive factors, and effect on clinical outcome (2008) (116)
Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients (2008) (114)
A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits. (1985) (108)
Cryptogenic stroke: time to determine aetiology (2008) (108)
Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study (2018) (108)
A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery (2007) (105)
Edoxaban: a focused review of its clinical pharmacology. (2014) (105)
Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. (2009) (105)
A Randomised, Double-Blind, Placebo-Controlled Trial of Dermatan Sulphate for Prevention of Deep Vein Thrombosis in Hip Fracture (1992) (104)
Venous thromboembolism after laparoscopic bariatric surgery for morbid obesity: clinical burden and prevention. (2012) (103)
Endothelial dysfunction in patients with spontaneous venous thromboembolism. (2007) (101)
The Comparative Effects of Recombinant Hirudin (CGP 39393) and Standard Heparin on Thrombus Growth in Rabbits (1990) (97)
A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement (2007) (97)
Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopatic deep venous thrombosis. (2001) (95)
Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study (2011) (95)
Neuroimaging in Intracerebral Hemorrhage (2014) (91)
Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta‐analysis of controlled studies (2011) (91)
Multidetector CT scan for acute pulmonary embolism: embolic burden and clinical outcome. (2012) (90)
The MASTER registry on venous thromboembolism: description of the study cohort. (2008) (90)
Management of venous thromboembolism in patients with cancer (2011) (90)
Prognostic role of embolic burden assessed at computed tomography angiography in patients with acute pulmonary embolism: systematic review and meta‐analysis (2013) (90)
What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke? (2007) (89)
Outcome in Patients with Stroke Associated with Internal Carotid Artery Occlusion (2005) (88)
Randomised, Double Blind, Multicentre, Placebo Controlled Study of Sulodexide in the Treatment of Venous Leg Ulcers (2002) (87)
Systemic Thrombolysis in Patients With Acute Ischemic Stroke and Internal Carotid ARtery Occlusion: The ICARO Study (2012) (87)
Thrombolytic Therapy for Thromboembolism of Vertebrobasilar Artery (1983) (87)
Prevention of venous thromboembolism after acute ischemic stroke (2005) (87)
Arterial hypertension as risk factor for spontaneous cervical artery dissection. A case–control study (2005) (86)
Venous thromboembolism and atherosclerosis: common denominators or different diseases? (2006) (86)
Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta‐analysis (2010) (85)
Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non–Vitamin‐K Oral Anticoagulants (RAF‐NOACs) Study (2017) (82)
Utility of an integrated clinical, echocardiographic, and venous ultrasonographic approach for triage of patients with suspected pulmonary embolism. (1998) (80)
To drain or not to drain extraperitoneal colorectal anastomosis? A systematic review and meta‐analysis (2014) (79)
Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. (2005) (79)
Acute Hyperglycemia and Early Hemorrhagic Transformation in Ischemic Stroke (2009) (77)
Acute pulmonary embolism: external validation of an integrated risk stratification model. (2013) (77)
Incidental venous thromboembolism in oncology patients (2012) (77)
Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52,693 patients in the Global Registry of Acute Coronary Events. (2010) (76)
Morbidity and mortality associated with atherosclerotic peripheral artery disease: A systematic review. (2020) (75)
D-Dimer for risk stratification in patients with acute pulmonary embolism (2011) (75)
Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits. (1985) (74)
[New antithrombotic drugs]. (1999) (72)
Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation (2003) (71)
Treatment of DVT: how long is enough and how do you predict recurrence (2008) (69)
Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation (2019) (69)
Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis (2020) (69)
A prospective study on cardiovascular events after acute pulmonary embolism (2005) (68)
Atrial fibrillation in patients with first‐ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome (2005) (66)
Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECHT and TOPIC‐2 studies (2010) (65)
Intravenous Thrombolysis with rt-PA in Acute Ischemic Stroke Patients Aged Older than 80 Years in Italy (2007) (65)
Gender Differences in Patients with Acute Ischemic Stroke (2010) (65)
Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin. (1992) (65)
Effect of peritoneal dialysis, haemodialysis and kidney transplantation on blood platelet function. I. Platelet aggregation by ADP and epinephrine. (1979) (64)
The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: influence of dosage regimens in rabbits. (1985) (63)
Perioperative Stroke Risk in Nonvascular Surgery (2012) (63)
Risk Stratification of Patients With Acute Symptomatic Pulmonary Embolism Based on Presence or Absence of Lower Extremity DVT: Systematic Review and Meta-analysis. (2016) (63)
Hormone replacement therapy and stroke. (2008) (62)
The management of acute venous thromboembolism in clinical practice (2017) (62)
Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta‐analysis (2007) (61)
Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study. (2002) (61)
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX‐2) (2010) (61)
Novel approaches to the treatment of thrombosis. (2002) (61)
Clinically overt venous thromboembolism after urologic cancer surgery: results from the @RISTOS Study. (2007) (61)
Prognostic relevance of an asymptomatic venous thromboembolism in patients with cancer (2011) (60)
Venous Thromboembolism (VTE) Prevention with Semuloparin in Cancer Patients Initiating Chemotherapy: Benefit-Risk Assessment by VTE Risk in SAVE-ONCO (2011) (59)
Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature. (2012) (59)
Factors associated with the timing of diagnosis of venous thromboembolism: results from the MASTER registry. (2008) (59)
Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. (2005) (58)
Diagnosis of deep vein thrombosis in asymptomatic high-risk patients. (1995) (57)
Admission leukocytosis in acute cerebral ischemia: influence on early outcome. (2012) (57)
Dermatan Sulphate for the Prevention of Postoperative Venous Thromboembolism in Patients with Cancer (1999) (56)
Treatment of Venous Thromboembolism With New Anticoagulant Agents. (2016) (53)
Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK). (2018) (53)
Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. (2005) (53)
Early admission to stroke unit influences clinical outcome (2006) (53)
Epidemiology of cerebral vein and sinus thrombosis. (2008) (52)
Risk of Recurrent Cerebrovascular Events in Patients with Cryptogenic Stroke or Transient Ischemic Attack and Patent Foramen Ovale: The FORI (Foramen Ovale Registro Italiano) Study (2010) (51)
Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life. (2017) (51)
Predictors of mortality from pulmonary embolism and their influence on clinical management (2008) (51)
Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer. (2019) (50)
Isolated monoparesis following stroke (2005) (50)
Rationale for bolus t-PA therapy to improve efficacy and safety. (1990) (50)
Should oral anticoagulants be restarted after warfarin-associated cerebral haemorrhage in patients with atrial fibrillation? (2013) (49)
Detection of Asymptomatic Deep Vein Thrombosis by Real-Time B-Mode Ultrasonography in Hip Surgery Patients (1992) (49)
Aspirin for prevention and treatment of venous thromboembolism. (2014) (49)
Effects of Standard Heparin and a Low Molecular Weight Heparin (Kabi 2165) on Fibrinolysis (1988) (49)
Acute pulmonary embolism: risk stratification in the emergency department (2007) (48)
DDAVP Induces Systemic Release of Urokinase-Type Plasminogen Activator (1989) (48)
Diagnosis of deep-vein thrombosis using an objective Doppler method. (1990) (47)
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study (2022) (47)
The management of acute venous thromboembolism in clinical practice – study rationale and protocol of the European PREFER in VTE Registry (2015) (47)
Oral anticoagulation in atrial fibrillation: A pan-European patient survey. (2007) (46)
Complications and functional outcomes after total hip arthroplasty and total knee arthroplasty: results from the Global Orthopaedic Registry (GLORY). (2010) (46)
Hemorrhagic Transformation in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Time to Initiation of Oral Anticoagulant Therapy and Outcomes (2018) (46)
Anticoagulation in patients with isolated distal deep vein thrombosis: a meta‐analysis (2017) (46)
Impedance plethysmography in the diagnosis of asymptomatic deep vein thrombosis in hip surgery. A venography-controlled study. (1991) (45)
Post Discharge Clinically Overt Venous Thromboembolism in Orthopaedic Surgery Patients with Negative Venography -an Overview Analysis (1996) (45)
Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. (1995) (44)
Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation (2016) (44)
Bosentan for chronic thromboembolic pulmonary hypertension: findings from a systematic review and meta-analysis. (2010) (44)
Cervical Artery Dissection: Emerging Risk Factors (2010) (44)
The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta‐analysis (2020) (43)
Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study (2020) (43)
Seasonal Variation in the Occurrence of Venous Thromboembolism: Data From the MASTER Registry (2009) (43)
Thrombolysis in hemodynamically stable patients with acute pulmonary embolism: a meta-analysis. (2014) (43)
Venous Thromboembolism and Gancer: a Two-Way Clinical Association (1997) (42)
Long-term death and recurrence in patients with acute venous thromboembolism: the MASTER registry. (2012) (42)
Obesity and the Risk of Intracerebral Hemorrhage: The Multicenter Study on Cerebral Hemorrhage in Italy (2013) (42)
Therapy Insight: venous-catheter-related thrombosis in cancer patients (2006) (41)
Effect of On-Admission Antiplatelet Treatment on Patients with Cerebral Hemorrhage (2007) (41)
Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. (2019) (41)
Prevention of Venous Thromboembolism After Neurosurgery (1999) (41)
Dose-Response Study of Recombinant Factor VIIa / Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c 2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement (2001) (41)
PRODIGE: A phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma (2007) (38)
Intravenous thrombolysis or endovascular therapy for acute ischemic stroke associated with cervical internal carotid artery occlusion: the ICARO-3 study (2015) (38)
Tranexamic acid, intrauterine contraceptive devices and fatal cerebral arterial thrombosis (1982) (38)
The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. (2011) (37)
Thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE]). (2009) (37)
The prophylaxis of venous thrombosis in patients with cancer undergoing major abdominal surgery: emerging options (2007) (36)
Risk factors for cerebral ischemic events in patients with atrial fibrillation on warfarin for stroke prevention. (2010) (36)
Cancer-associated ischemic stroke: A retrospective multicentre cohort study. (2018) (34)
Features of Thrombi and Diagnostic Accuracy of Impedance Plethysmography in Symptomatic and Asymptomatic Deep Vein Thrombosis (1993) (34)
Intravenous thrombolysis in acute myocardial infarction. (2001) (34)
Prediction of Early Recurrent Thromboembolic Event and Major Bleeding in Patients With Acute Stroke and Atrial Fibrillation by a Risk Stratification Schema: The ALESSA Score Study (2017) (33)
Antithrombotic medications and the etiology of intracerebral hemorrhage (2014) (33)
96 hours ECG monitoring for patients with ischemic cryptogenic stroke or transient ischaemic attack (2014) (32)
Cephalosporin-induced hypoprothrombinemia: is the N-methylthiotetrazole side chain the culprit? (1986) (32)
Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry (2019) (32)
Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options (2017) (32)
New anticoagulants for the prevention of venous thromboembolism (2010) (32)
Effects of desmopressin on hemostasis in patients with liver cirrhosis. (1995) (32)
Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery - the SAVE-HIP3 study. (2013) (32)
Prognostic value of trans-thoracic echocardiography in patients with acute stroke and atrial fibrillation: findings from the RAF study (2016) (31)
Acute myocardial infarction and heart failure in acute stroke patients: frequency and influence on clinical outcome (2011) (31)
Corrigendum to: 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. (2015) (31)
Efficacy of Rivaroxaban for thromboprophylaxis after Knee Arthroscopy (ERIKA) (2016) (30)
Health-related quality of life and mortality in patients with pulmonary embolism: a prospective cohort study in seven European countries (2019) (30)
Low molecular weight heparins (1998) (30)
Incidence of Ct scan-detected pulmonary embolism in patients with oncogene-addicted, advanced lung adenocarcinoma. (2015) (30)
Preoperative Enoxaparin Versus Postoperative Semuloparin Thromboprophylaxis in Major Abdominal Surgery: A Randomized Controlled Trial (2014) (30)
Predictive value of admission blood glucose level on short-term mortality in acute cerebral ischemia. (2012) (30)
APIXABAN FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS: DATA FROM THE AMPLIFY TRIAL (2014) (30)
Bolus thrombolysis in venous thromboembolism. (1992) (30)
A Phase II Study of the Safety and Efficacy of a Novel Oral fXa Inhibitor (LY517717) for the Prevention of Venous Thromboembolism Following TKR or THR. (2005) (29)
An injectable implant to stimulate the sphenopalatine ganglion for treatment of acute ischaemic stroke up to 24 h from onset (ImpACT-24B): an international, randomised, double-blind, sham-controlled, pivotal trial (2019) (29)
The Ultra-Low-Molecular-Weight Heparin Semuloparin for Prevention of Venous Thromboembolism In Patients Undergoing Major Abdominal Surgery (2010) (29)
A prospective study on survival in cancer patients with and without venous thromboembolism (2013) (29)
The management of acute venous thromboembolism in clinical practice. (2017) (29)
Current Issues in Anticoagulation (2005) (28)
Prevention of venous thromboembolism. (2000) (28)
Risk factors for venous thromboembolism in the elderly: results of the master registry (2008) (28)
DESMOPRESSIN-INDUCED IMPROVEMENT OF ABNORMAL COAGULATION IN CHRONIC LIVER DISEASE (1983) (28)
Right ventricle assessment in patients with pulmonary embolism at low risk for death based on clinical models: an individual patient data meta-analysis. (2021) (28)
Withdrawal of warfarin after deep vein thrombosis: effects of a low fixed dose on rebound thrombin generation. (1999) (28)
Serum cholesterol levels, HMG-CoA reductase inhibitors and the risk of intracerebral haemorrhage. The Multicenter Study on Cerebral Haemorrhage in Italy (MUCH-Italy) (2016) (28)
Patients with cancer and atrial fibrillation treated with doacs: A prospective cohort study. (2018) (27)
Variation of renal function over time is associated with major bleeding in patients treated with direct oral anticoagulants for atrial fibrillation (2018) (27)
Comparison of utilization of statin therapy at hospital discharge and six-month outcomes in patients with an acute coronary syndrome and serum low-density lipoprotein>or=100 mg/dl versus<100 mg/dl. (2007) (27)
Anticoagulation After Stroke in Patients With Atrial Fibrillation. (2019) (27)
Management of oral anticoagulant therapy in Italy. (1999) (26)
YM150, an Oral Direct Factor Xa Inhibitor, as Prophylaxis for Venous Thromboembolism in Patients with Elective Primary Hip Replacement Surgery. A Dose Escalation Study. (2005) (26)
Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. (2021) (26)
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations (2018) (26)
Effect of pentoxifylline on platelet aggregation. (1981) (26)
Permanent discontinuation of non vitamin K oral anticoagulants in real life patients with non-valvular atrial fibrillation. (2017) (26)
Prevention of venous thromboembolism in immobilized neurological patients: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). (2009) (26)
Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes) (2017) (25)
A Randomized Double-Blind Placebo-Controlled Study on Nadroparin for Prophylaxis of Thromboembolic Events in Cancer Patients Receiving Chemotherapy: The PROTECHT Study (2008) (25)
Postoperative pulmonary embolism detected with multislice computed tomography in lung surgery for cancer. (2006) (25)
Incidence and risk factors for venous thromboembolism after laparoscopic surgery for colorectal cancer (2015) (24)
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE‐HIP1, SAVE‐HIP2 and SAVE‐KNEE (2012) (24)
Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. (2018) (24)
Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis. (2018) (23)
Magnetic resonance imaging, magnetic resonance and catheter angiography for diagnosis of cervical artery dissection. (2005) (23)
Prior use of antithrombotic agents and neurological functional outcome at discharge in patients with ischemic stroke (2006) (23)
Risk assessment for recurrence and optimal agents for extended treatment of venous thromboembolism. (2013) (23)
Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). (2007) (23)
Need for extensive diagnostic work-up for patients with lacunar stroke (2008) (22)
Intravenous Thrombolysis for Acute Ischemic Stroke Associated to Extracranial Internal Carotid Artery Occlusion: The ICARO-2 Study (2012) (22)
Severity of acute intracerebral haemorrhage, elderly age and atrial fibrillation: independent predictors of poor outcome at three months. (2013) (22)
The effect of low-molecular-weight heparin in cancer patients: the mirror image of survival? (2014) (22)
Do Italian vascular centers look for isolated calf deep vein thrombosis? Analysis of isolated calf deep vein thromboses included in the ''Master'' Registry. (2008) (22)
The rationale for long-term prophylaxis of venous thromboembolism. (2000) (22)
Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis (2017) (21)
Padua prediction score or clinical judgment for decision making on antithrombotic prophylaxis: a quasi-randomized controlled trial (2016) (21)
Performance of recalibrated ReFacto® laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one‐stage assays after infusion of recalibrated ReFacto® (B‐domain deleted recombinant factor VIII) (2009) (21)
Clinical Outcome of Orthopaedic Patients with Negative Lower Limb Venography at Discharge (1995) (20)
Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis. (1993) (20)
Statins and Stroke Prevention (2007) (20)
Management of asymptomatic carotid stenosis in patients undergoing general and vascular surgical procedures (2005) (20)
Non-neurological complications of acute stroke: frequency and influence on clinical outcome (2011) (20)
Effects of Hirudin and Heparin on the Binding of New Fibrin to the Thrombus in t-PA Treated Rabbits (1991) (20)
ACUTE TREATMENT OF VENOUS THROMBOEMBOLISM. (2019) (20)
Deep Vein Thrombosis in Europe—Health-Related Quality of Life and Mortality (2019) (20)
Anticoagulation in the prevention and treatment of pulmonary embolism. (1995) (20)
Anticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach (2015) (20)
Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction. (1995) (20)
Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients (2019) (19)
Thrombosis and cancer: clinical relevance of a dangerous liaison. (2005) (19)
Risk stratification and management of acute pulmonary embolism. (2016) (19)
Risk factors for adverse short-term outcome in patients with pulmonary embolism. (2001) (19)
Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics. (2002) (19)
Patients aged 90 years or older with atrial fibrillation treated with oral anticoagulants: A multicentre observational study. (2019) (19)
Risk of recurrent venous thromboembolism after acute pulmonary embolism: Role of residual pulmonary obstruction and persistent right ventricular dysfunction. A meta‐analysis (2019) (18)
New oral anticoagulants for the treatment of venous thromboembolism. (2013) (18)
Activation of blood coagulation in patients undergoing postoperative blood salvage and re-infusion of unwashed whole blood after total knee arthroplasty. (2004) (18)
Thromboprophylaxis during chemotherapy in patients with advanced cancer. (2010) (18)
Lung ultrasound in the diagnosis of stroke-associated pneumonia (2014) (18)
Thrombus resistance to lysis and reocclusion after thrombolysis: the role of platelets. (1991) (18)
High diastolic blood pressure is a risk factor for in-hospital mortality in complete MCA stroke patients (2012) (18)
Diagnosis and prognosis of acute pulmonary embolism: focus on serum troponins (2008) (17)
A commentary: To screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry (2007) (17)
Hyperdense Middle Cerebral and/or Internal Carotid Arteries in Acute Ischemic Stroke: Rate, Predictive Factors and Influence on Clinical Outcome (2011) (17)
Clinical Benefit of Early Anticoagulation in Cardioembolic Stroke (2008) (17)
The complexity of patients hospitalized in Internal Medicine wards evaluated by FADOI-COMPLIMED score(s). A hypothetical approach (2018) (17)
Diagnostic Accuracy of Computerized Impedance Plethysmography in the Diagnosis of Symptomatic Deep Vein Thrombosis: A Controlled Venographic Study (1990) (17)
Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer (2021) (17)
Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer (2015) (17)
Efficacy and safety of direct oral anticoagulants after pulmonary embolism: a meta-analysis. (2014) (17)
Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life. (2016) (16)
Fibrin clots obtained from plasma containing heparin show a higher sensitivity to t‐PA-induced lysis (1992) (16)
Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. (2016) (16)
Pharmacological activities of heparin chains: should our past knowledge be revised? (1996) (16)
Prediction of major bleeding in patients receiving DOACs for venous thromboembolism: A prospective cohort study. (2019) (16)
Determinants of outcome in patients eligible for thrombolysis for ischemic stroke (2007) (16)
Current role of venography in the diagnosis of deep-vein thrombosis. (1998) (16)
Prevalence of risk factors for venous thromboembolism in the Italian population: results of a cross-sectional study from the Master Registry (2013) (16)
Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy (2015) (16)
Carotid atherosclerosis and risk for ischemic stroke in patients with atrial fibrillation on oral anticoagulant treatment. (2018) (16)
Postoperative Melagatran/ Ximelagatran for the Prevention of Venous Thromboembolism following Major Elective Orthopaedic Surgery (2005) (16)
Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism (2019) (16)
A double-blind placebo-controlled randomized study on the efficacy and safety of enoxaparin for the prevention of upper limb deep vein thrombosis in cancer patients with central vein catheter (2004) (16)
Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt‐PA for pulmonary embolism (1997) (15)
Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study (2021) (15)
Study DVT Dose-Ranging - symptomatic deep vein thrombosis: the Einstein factor Xa inhibitor rivaroxaban in the treatment of patients with acute A dose-ranging study evaluating once-daily oral administration of the (2013) (15)
Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study (2019) (15)
New and old anticoagulants in cancer. (2012) (15)
Mortality in patients with intracerebral hemorrhage associated with antiplatelet agents, oral anticoagulants or no antithrombotic therapy. (2020) (15)
Thrombolytic Activity of Two Chimeric Recombinant Plasminogen Activators (FK2tu-PA and K2tu-PA) in Rabbits (1992) (15)
Alcohol intake and the risk of intracerebral hemorrhage in the elderly (2018) (15)
OC-01 Prognostic relevance of asymptomatic venous thromboembolism in patients with cancer (2010) (15)
Handbook on Cerebral Venous Thrombosis (2007) (15)
Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study (2018) (14)
Oxygen saturation or respiratory rate to improve risk stratification in hemodynamically stable patients with acute pulmonary embolism (2018) (14)
Prevention of venous thromboembolism in high risk patients. (1997) (14)
Role of fibrinolysis and interventional therapy for acute venous thromboembolism (2006) (14)
Beta-lactam antibiotics and vitamin K. (1992) (14)
Dermatan sulphate in patients with heparin‐induced thrombocytopenia (1999) (14)
Efficacy and Safety of Anticoagulant Treatment in Acute Cardioembolic Stroke (2007) (14)
Venous thromboembolism after laparoscopic cholecystectomy: clinical burden and prevention (2013) (13)
Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study (2021) (13)
Optimizing therapy with anticoagulants: risk analysis and socio-economic perspectives. Preface. (1999) (13)
Prevention of venous thromboembolism after acute spinal cord injury with low-dose heparin or low-molecular-weight heparin (2008) (13)
Deep-vein thrombosis in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. (2018) (13)
Attitudes to prescribing compression stockings for patients with acute dvt: the MASTER registry (2009) (13)
Prognostic value of respiratory index in haemodynamically stable patients with acute pulmonary embolism: The Respiratory Index model study (2020) (13)
Direct oral anticoagulants in the secondary prevention of stroke and transient ischemic attack in patients with atrial fibrillation (2015) (13)
Acute stroke symptoms: do differences exist between sexes? (2014) (13)
Thrombin plays a pivotal role in vascular re-occlusion after PTCA and coronary thrombolysis. (1996) (13)
Treatment of acute, symptomatic, proximal deep vein thrombosis with the oral, direct Factor Xa inhibitor rivaroxaban (BAY 59-7939) - the ODIXa-DVT dose-ranging study (2006) (13)
Risk-prediction model for ischemic stroke in patients hospitalized with an acute coronary syndrome (from the global registry of acute coronary events [GRACE]). (2012) (13)
Additive Effect of dDAVP and Standard Heparin inIncreasing Plasma t-PA (1989) (13)
Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin (2016) (13)
Manifestations of Stroke (2012) (12)
Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial (2019) (12)
Thrombolytic and Haemorrhagic Effects of Bolus Doses of Tissue-Type Plasminogen Activator and a Hybrid Plasminogen Activator with Prolonged Plasma Half-Life (K2tu-PA: CGP 42935) (1993) (12)
Persistent spontaneous heparinaemia in systemic mastocytosis. (1982) (12)
Safety of catheter ablation of atrial fibrillation in cancer survivors (2020) (12)
Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3) (2013) (12)
Effects of a stable prostacyclin analogue on platelet activity and on host immunocompetence in mice. (1990) (12)
Combined oral anticoagulants and antiplatelets: benefits and risks (2010) (12)
Effects of the new glycopeptide antibiotic teicoplanin on platelet function and blood coagulation (1987) (12)
Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism (2021) (12)
Right ventricle dysfunction in patients with pulmonary embolism (2010) (12)
Cardiac Hemangioma of the Right Atrium: A Possible Cause of Cerebellar Stroke (2007) (11)
Clinically relevant non-major bleeding with oral anticoagulants: non-major may not be trivial. (2018) (11)
Intrinsically Defective or Exhausted Platelets in Hairy Cell Leukemia? (1981) (11)
Bedside sonography assessment of extravascular lung water increase after major pulmonary resection in non-small cell lung cancer patients. (2018) (11)
Biphasic sulphinpyrazone-warfarin interaction. (1981) (11)
State of play and future direction with NOACs: An expert consensus. (2018) (11)
Concomitant Use of Direct Oral Anticoagulants and Antiepileptic Drugs: A Prospective Cohort Study in Patients with Atrial Fibrillation (2020) (11)
Properties of Chimeric (Tissue-Type/Urokinase-Type) Plasminogen Activators Obtained by Fusion at the Plasmin Cleavage Site (1993) (11)
Pre-operative plasma levels of soluble fibrin polymers correlate with the development of deep vein thrombosis after elective neurosurgery. (1999) (11)
Effects of therapeutic doses of heparin on thrombolysis with tissue- type plasminogen activator in rabbits (1990) (11)
Recombinant hirudin in the prevention of venous thromboembolism in patients undergoing elective hip surgery. (1997) (11)
Pharmacokinetic Optimisation of the Treatment of Deep Vein Thrombosis (1997) (11)
New oral anticoagulants: just a new therapeutic option or a real breakthrough? (2009) (11)
Acute cardiovascular events in patients with community acquired pneumonia: results from the observational prospective FADOI-ICECAP study (2021) (11)
Once Daily YM150, an Oral Direct Factor Xa Inhibitor, for Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Hip Replacement. (2007) (10)
Once- or Twice-Daily Rivaroxaban for the Treatment of Proximal Deep Vein Thrombosis: Similar Efficacy and Safety to Standard Therapy in Dose-Ranging Studies. (2006) (10)
Holter monitoring to detect silent atrial fibrillation in high-risk subjects: the Perugia General Practitioner Study (2015) (10)
Building effective prophylaxis of deep vein thrombosis in the outpatient setting. (1999) (10)
Pathogenesis of venous thromboembolism. (2002) (10)
Sex Difference in Circulating Platelet Aggregates and Response to Antiplatelet Treatment (1982) (10)
The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry. (2017) (10)
Recurrent venous thromboembolism in men and women. (2004) (10)
Effect of DDAVP on plasma level of factor XII (1983) (10)
Experimental Pharmacology of Hirunorm: a Novel Synthetic Peptide Thrombin Inhibitor (1996) (10)
Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes (2007) (10)
The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design (2019) (10)
Dermatan sulphate in heparin-induced thrombocytopenia (1994) (10)
Intramuscular Dermatan Sulfate MF701 in Patients with Hip Fracture: Relationship between Pharmacokinetics and Antithrombotic Efficacy (1994) (10)
Prognostic assessment (2018) (9)
Corrigendum to: 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. (2015) (9)
Clinical status of direct thrombin inhibitors. (1999) (9)
[Comments on the guidelines of the European Society of Cardiology Task Force on pulmonary embolism]. (2001) (9)
Symptoms and clinical relevance: A dilemma for clinical trials on prevention of venous thromboembolism (2013) (9)
Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. (2020) (9)
Is antithrombotic prophylaxis required in cancer patients with central venous catheters? No (2006) (9)
Acute thrombocytopenia following oral cholecystography with iopanoic acid. (1981) (9)
Successful treatment with dermatan sulfate in six patients with heparin‐induced thrombocytopenia and acute venous thromboembolism (2003) (9)
Clinical and economic aspects of managing venous thromboembolism in the outpatient setting. (2001) (9)
Infusion of vincristine-loaded platelets in acute ITP refractory to steroids: an alternative to splenectomy. (1981) (9)
Definition of major bleeding: Prognostic classification (2020) (9)
Long‐term low‐dose warfarin use is effective in the prevention of recurrent venous thromboembolism: no (2004) (9)
Mucus-secreting 'signet-ring' cells in CSF revealing the site of primary cancer. (1980) (9)
New strategies of VTE prevention in cancer patients. (2014) (9)
Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baseline risk factors. Insights from the PREFER in VTE. (2021) (8)
Efficacy of Thrombolytic (rt-PA) Therapy in Old Stroke Patients: The Perugia Stroke Unit Experience (2006) (8)
Direct Oral Anticoagulants in Patients With VTE and Cancer (2014) (8)
Effect on thrombus growth and thrombolysis of two types of osmolar contrast media in rabbits. (1990) (8)
Risk Profile of Symptomatic Lacunar Stroke Versus Nonlobar Intracerebral Hemorrhage (2016) (8)
Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence (2017) (8)
Clinical presentation and in-hospital death in acute pulmonary embolism: does cancer matter? (2016) (8)
Optimal dosage regimens of tissue-type plasminogen activator. (1987) (8)
Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial (2020) (8)
A clinical outcome-based prospective study on venous thromboembolism in cancer surgery: the @RISTOS project (2003) (8)
Rivaroxaban for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Design of the PRO-LAPS II STUDY. (2019) (8)
Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide (2017) (8)
Initial treatment of venous thromboembolism (2006) (8)
Thromboprophylaxis with Low-Molecular-Weight Heparins: An Assessment of the Methodological Quality of Studies (2015) (8)
Thromboprophylaxis during chemotherapy after advanced cancer. (2007) (8)
Current Concepts Acute Pulmonary Embolism (2010) (8)
Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis (2021) (8)
Fatal Nocardia farcinica Bacteremia Diagnosed by Matrix-Assisted Laser Desorption-Ionization Time of Flight Mass Spectrometry in a Patient with Myelodysplastic Syndrome Treated with Corticosteroids (2013) (8)
Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry (2018) (8)
Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities (2009) (8)
Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry (2018) (8)
Derivation and Validation of a Prediction Model for Venous Thromboembolism in Primary Care (2020) (7)
Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis (2017) (7)
SMASH-U classification: a tool for aetiology-oriented management of patients with acute haemorrhagic stroke (2020) (7)
Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study (2022) (7)
The impact of co-morbidity on the disease burden of VTE (2017) (7)
Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives (2021) (7)
Two Doses of Apixaban for the Extended Treatment of Venous Thromboembolism (2012) (7)
PO-40 PRODIGE: a randomized placebo-controlled trial of long-term thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma: updated results (2007) (7)
Hormone-Replacement Therapy, Dementia and Stroke (2007) (7)
Acute hematoma expansion after spontaneous intracerebral hemorrhage: risk factors and impact on long-term prognosis (2020) (7)
Vincristine-loaded platelets for autoimmune thrombocytopenic purpura (letter) (1982) (7)
Spiral computed tomography is the first‐line chest imaging test for acute pulmonary embolism: no (2005) (7)
Postdischarge prophylaxis for venous thromboembolism among high-risk surgery patients (1998) (7)
A randomized double blind placebo controlled trial of MF 701 Dermatan sulphate for prevention of deep vein thrombosis (DVT) in hip fracture (1990) (7)
Vinca-loaded platelets. (1984) (7)
Aspirin After Oral Anticoagulants for Prevention of Recurrence in Patients with Unprovoked Venous Thromboembolism. the Warfasa STUDY (2011) (7)
Effect of carotid stenosis on the prognostic value of admission blood pressure in patients with acute ischemic stroke. (2009) (7)
Assessment of Bleeding after Concomitant Administration of Antiplatelet and Anticoagulant Agents in Lower Limb Arthroplasty (2006) (7)
Comparison of antithrombotic strategies in patients with cryptogenic stroke and patent foramen ovale: an updated meta-analysis (2020) (6)
Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention (2020) (6)
New oral anticoagulants for venous thromboembolism: focus on factor Xa and thrombin inhibitors. (2012) (6)
A double-blind placebo-controlled randomized study on the efficacy and safety of enoxaparin for the prevention of upper limb deep vein thrombosis in cancer patients with central vein catheter. (2004) (6)
Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy: Results From a Global Prospective Cohort Study (2017) (6)
Treatment of venous thromboembolism in cancer patients: The dark side of the moon. (2021) (6)
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein Thrombosis (DVT). (2007) (6)
Clinical Potential of Oral Direct Thrombin Inhibitors in the Prevention and Treatment of Venous Thromboembolism (2004) (6)
The Additive Effect of Low Molecular Weight Heparins on Thrombin Inhibition by Dermatan Sulfate (1993) (6)
Comparison of quality of life measurements: EQ-5D-5L versus disease/treatment-specific measures in pulmonary embolism and deep vein thrombosis (2019) (6)
Platelet-tumor cell interaction: effect of prostacyclin and a synthetic analog on metastasis formation (2004) (6)
End points in studies on the prevention of deep vein thrombosis. (2001) (6)
Upper extremities deep vein thrombosis treated with oral direct anticoagulants: A prospective cohort study. (2021) (6)
A Hybrid Plasminogen Activator Binds to the u-PA Receptor and Has a Reduced Thrombolytic Potency In Vivo (1993) (6)
Biosimilars of low‐molecular‐weight heparin products: fostering competition or reducing ‘biodiversity’? (2016) (6)
Emerging therapies for stroke prevention in atrial fibrillation (2005) (6)
Significantly lower need for blood transfusions associated with post-operatively initiated subcutaneous melagatran/oral ximelagatran compared with enoxaparin (2004) (6)
Novel oral anticoagulants for patients with venous thromboembolism and active cancer: a systematic review and meta-analysis (2014) (6)
Effects of therapeutic doses of heparin on thrombolysis with tissue-type plasminogen activator in rabbits. (1990) (6)
Clinical experience with low molecular weight heparins. (1990) (6)
Plasma thrombin neutralization assay: pharmacokinetic applications. (1994) (5)
More on: vitamin K antagonists and cancer (2008) (5)
Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer (2022) (5)
Sunday, 26 August 2012 (2012) (5)
Low levels of low-density lipoprotein cholesterol increase hemorrhagic transformation but not parenchimal hematoma in large artery atherothrombosisis. (2009) (5)
The management of patients with venous thromboembolism in Italy: insights from the PREFER in VTE registry (2016) (5)
Lacunar stroke syndromes as predictors of lacunar and non-lacunar infarcts on neuroimaging: a hospital-based study (2019) (5)
Mechanisms of the antimetastatic activity of stable prostacyclin analogues: modulation of host immunocompetence. (1991) (5)
Interactions between thrombophilic genetic mutations and clinical bleeding in patients on chronic oral anticoagulant treatment. (2005) (5)
Human Pharmacokinetics and Pharmacodynamics of MF 701 Dermatan Sulfate Administered by Continuous Intravenous Infusion (1990) (5)
Early recurrence in paroxysmal versus sustained atrial fibrillation in patients with acute ischaemic stroke (2018) (5)
Low-Molecular-Weight Heparins in the Management of Unstable Angina (2000) (5)
Prestroke CHA2DS2-VASc Score and Severity of Acute Stroke in Patients with Atrial Fibrillation: Findings from RAF Study. (2017) (5)
PREvention of VENous Thromboembolism in Hemorrhagic Stroke Patients – PREVENTIHS Study: A Randomized Controlled Trial and a Systematic Review and Meta-Analysis (2020) (5)
Thrombolysis in elderly stroke patients in Italy (TESPI) trial and updated meta-analysis of randomized controlled trials (2019) (5)
Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study. (2022) (5)
Rationale for the use of platelet aggregation inhibitors in PAD patients (2001) (5)
Local versus Central Assessment of Venographies in a Multicenter Trial on the Prevention of Deep Vein Thrombosis in Neurosurgery (1999) (5)
Time in Therapeutic Range (TTR) and Relative Efficacy and Safety of Treatment with Apixaban or Enoxaparin/Warfarin for Acute Symptomatic Venous Thromboembolism: An Analysis of the Amplify Trial Data (2014) (5)
Prophylaxis against venous thromboembolism in patients with cancer. (2014) (5)
Rationale for the bolus administration of fibrin-specific thrombolytic agents (1997) (4)
ESC position paper Anticoagulants in heart disease : current status and perspectives ‡ (2007) (4)
Venous thromboembolism and COVID-19: Mind the gap between clinical epidemiology and patient management (2020) (4)
Home management or hospital admission for low-risk pulmonary embolism? Clinical scores versus pragmatic assessment. (2021) (4)
Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention (2021) (4)
ACCP Conference on Antithrombotic and Thrombolytic Therapy Antithrombotic Therapy for Venous Thromboembolic Disease : The Seventh (2004) (4)
Antithrombotic therapy for patients with an indication for oral anticoagulation undergoing percutaneous coronary intervention with stent: The case of venous thromboembolism. (2018) (4)
Treatment Satisfaction In Patients With Venous Thromboembolism As Measured With Pact-Q2: Prefer In Vte Registry. (2014) (4)
A nomogram to predict unfavourable outcome in patients receiving oral anticoagulants for atrial fibrillation after stroke (2020) (4)
Strategies for administration of tissue plasminogen activator. (1991) (4)
Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis. (2021) (4)
Direct oral anticoagulants for secondary prevention in patients with non-valvular atrial fibrillation (2013) (4)
Thrombolytic and antithrombotic treatment in myocardial infarction: main achievements and future perspectives. (1995) (4)
Angiographic Findings of Moyamoya Vessels in a Patient with Rheumatoid Arthritis (2005) (4)
Risk factors and one-year mortality in patients with direct oral anticoagulant-associated gastrointestinal bleeding. (2021) (4)
Safety of the combination of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors: observations from the global registry of acute coronary events (GRACE) (2001) (4)
[Impedance plethysmography, Doppler echography and phlebography in deep venous thromboses of the lower limbs]. (1990) (4)
Visual dysfunctions. (2012) (4)
ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. (2020) (4)
Long-term outcome in patients with non-valvular atrial fibrillation on dabigatran: a prospective cohort study (2018) (4)
The year in cardiology 2016: peripheral circulation. (2017) (4)
Direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery. (2005) (4)
Rates and Determinants for the Use of Anticoagulation Treatment before Stroke in Patients with Known Atrial Fibrillation (2020) (4)
Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model (2017) (4)
Prolonged prophylaxis against venous thromboembolism with enoxaparin in patients undergoing cancer surgery: long-term survival analysis (2006) (4)
Erratum to: Guidance for the treatment of deep vein thrombosis and pulmonary embolism (2016) (4)
Non-Anticoagulant Actions of Glycosaminoglycans (1996) (3)
Thromboprophylaxis in acutely ill medical patients: results of a survey among Italian physicians. (2014) (3)
FACTOR‐VIIcoag KINETICS IN FACTOR‐VII‐CRM+ AND FACTOK‐ VII‐CKM‐DEFICIENCIES (1980) (3)
3001 POSTER DISCUSSION Ultra-low-molecular-weight Heparin (ULMWH) Semuloparin for Prevention of Venous Thromboembolism (VTE) in Cancer Patients Receiving Chemotherapy: Consistent Beneficial Effect Across Cancer Stage and Location Subgroups (2011) (3)
Inhibition of Spontaneous Platelet Aggregation by Sulfinpyrazone (1979) (3)
Unmet clinical needs in the prevention and treatment of cancer-associated venous thromboembolism. (2022) (3)
Multicenter, prospective, case-control, observational study on the influence of venous thromboembolism on patient outcome. (2011) (3)
Medicine before and after David Cox. (2022) (3)
New pharmacologic strategies for arterial and venous thromboembolism. (2001) (3)
More on Platelet-Rich Plasma Injections in Acute Muscle Injury (2014) (3)
Health State In Patients With Venous Thromboembolism On Conventional And Non-Vka Oral Anticoagulants As Assessed With The Eq-5d-5l Questionnaire: Prefer In Vte Registry. (2014) (3)
Acute Pulmonary Embolism after Discharge: Duration of Therapy and Follow-up Testing (2017) (3)
Role of Internal Jugular Vein Ultrasound Measurements in the Assessment of Central Venous Pressure in Spontaneously Breathing Patients: A Systematic Review. (2019) (3)
Evaluating bleeding complications of thromboprophylaxis after hip replacement: a systematic review (2003) (3)
Clinical management and outcome of major bleeding in patients on treatment with vitamin K antagonists. (2016) (3)
The high-risk bleeding category of different scores in patients with venous thromboembolism: Systematic review and meta-analysis. (2021) (3)
Timing of initiation of oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation comparing posterior and anterior circulation strokes (2020) (3)
Effect of dermatan sulphate on activated partial thromboplastin time determined with different reagents. (1997) (3)
Safety of Anticoagulation in Patients Treated With Urgent Reperfusion for Ischemic Stroke Related to Atrial Fibrillation (2020) (3)
Stroke pharmacogenomics (2009) (3)
Treatment of venous thromboembolism: unfractionated heparin or low molecular weight heparins? (1995) (3)
Choice of End-points in Assessing the Efficacy of Post-discharge Prophylaxis for Venous Thromboembolism (1998) (3)
Efficacy and safety of new oral anticoagulants compared with warfarin in cardioembolic prophylaxis of patients with non valvular atrial fibrillation. More lights than shadows (2012) (3)
Clotting activation after blood transfusion in patients receiving 5-fluorouracil and mitomycin-C treatment (2004) (3)
Evaluation, risk stratification and management of hypertensive patients in the perioperative period. (2019) (3)
Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism (2018) (3)
Prophylaxis of upper limb deep vein thrombosis in cancer patients with central vein catheter (2008) (3)
Survival benefit with low-molecular-weight heparin in patients with advanced solid tumors: A post hoc analysis of PROTECHT trial. (2014) (3)
ANALYSIS OF THE BLEEDING AND THROMBOEMBOLIC RISK WITH CONCOMITANT USE OF ANTIPLATELET TREATMENT IN THE AMPLIFY TRIAL (2014) (3)
Seizures, headache and thrombocytopenia: diagnosis and treatment do not always come in a standard sequence (2007) (2)
Gene-Drug Interaction in Stroke (2011) (2)
Effects of the monobactam antibiotic aztreonam on platelet function and blood coagulation. (1987) (2)
Predictors of Venous Thmromboembolism in Colorectal Cancer: Results from a Global Prospective Study (2016) (2)
Vitamin K antagonists and cancer: reply to rebuttal (2004) (2)
ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months. (2020) (2)
One-year outcomes in atrial fibrillation patients with versus without a previous stroke or transient ischaemic attack: findings from the international prospective GARFIELD registry (2013) (2)
Dermatan sulphate for heparin-induced thrombocytopenia and central venous catheter-related deep vein thrombosis in a child with acute lymphoblastic leukemia. (2004) (2)
Comprar Handbook on Cerebral Venous Thrombosis | Valeria Caso | 9783805583787 | Karger AG (2008) (2)
Treatment of venous thromboembolism in patients with cancer: from clinical trials to real life. (2020) (2)
Global prospective cohort study of factors associated with early mortality in patients with lung cancer undergoing chemotherapy. (2016) (2)
Early onset life-threatening myelosuppression after low dose of intravesical thiotepa (1982) (2)
Anticoagulant agents in the management of pulmonary embolism. (1998) (2)
Clinical skills or high-tech MR in TIA patients: what makes the difference? (2018) (2)
Heparin assay: a comparison between titrimetric and amidolytic methods. (1980) (2)
Latest developments in antithrombotic therapy in patients with lower extremity arterial disease (2014) (2)
Venous thromboembolism risk, prophylaxis and management in cancer patients with COVID-19: An unmet medical need (2022) (2)
Prophylaxis of Venous Thromboembolism after Hospital Discharge in Internal Medicine: Findings from the Observational FADOI-NoTEVole Study (2019) (2)
Effects of cefamandole on hemostasis in patients undergoing hip replacement with heparin prophylaxis. (1988) (2)
Sex-related differences in risk factors, type of treatment received and outcomes in patients with atrial fibrillation and acute stroke: Results from the RAF-study (Early Recurrence and Cerebral Bleeding in Patients with Acute Ischemic Stroke and Atrial Fibrillation) (2017) (2)
Cervical Artery Dissection: Emerging Risk Factors~!2009-05-11~!2010-12-31~!2010-06-14~! (2010) (2)
Lessons learned from the global orthopaedic registry: study design, current practice patterns, and future directions. (2010) (2)
The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. (2011) (2)
Thrombolysis therapy in octogenarians (2006) (2)
Solutions to Reduce Cardiovascular Events in Patients with Atrial Fibrillation. (2012) (2)
Subarachnoid Hemorrhage: A Neurological Emergency (2011) (2)
Heart failure and chronic kidney disease in a registry of internal medicine wards (2014) (2)
Khorana risk score: Is the body mass index a predictable factor for thromboembolism in European countries? A retrospective analysis. (2012) (2)
The comparative effects of recombinant hirudin and standard heparin on inhibition of thrombus growth in rabbits (1990) (2)
A sudden neurological deficit in a patient with endocarditis (2009) (2)
Predictors of clinically significant bleeding in colorectal cancer: Results from a global prospective cohort study. (2014) (2)
Vincristine-loaded platelets for autoimmune thrombocytopenic purpura. (1982) (2)
Efficacy and safety of new oral anticoagulants in prophylaxis and treatment of venous thromboembolism (2010) (2)
TREATMENT AND OUTCOMES OF PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION ACCORDING TO GUIDELINE-DEFINED ANTICOAGULATION THRESHOLDS: RESULTS FROM THE GARFIELD-AF REGISTRY (2017) (2)
Long-term therapy of pulmonary embolism. (2005) (2)
[Acute immunoallergic thrombopenia due to sulfamethoxazole-trimethoprim]. (1980) (2)
ICH in patients with primary or metastatic brain cancer treated or not with anticoagulants: a systematic review and meta-analysis. (2022) (2)
Impedance plethysmography (IPG) has high sensitivity and specificity in patients with symptomatic DVT while it fails to detect asymptomatic DVT: The causes of the discrepancy (1992) (2)
Predictors of early mortality in colorectal cancer patients undergoing chemotherapy: Results from a global prospective cohort study. (2014) (2)
Complexity of patients with chronic obstructive pulmonary disease hospitalized in internal medicine: a survey by FADOI (2015) (2)
New anticoagulants. (2006) (2)
RANDOMISED, OPEN, PROSPECTIVE, MULTICENTER PILOT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ACTIVATED RECOMBINANT FACTOR VIIA (NOVOSEVEN) IN ACUTE INTRACEREBRAL HAEMORRHAGE IN PATIENTS TREATED WITH ORAL ANTICOAGULANT OR ANTIPLATELET AGENTS (2007) (2)
Management of thromboembolism in the outpatient setting. (2000) (2)
Treatment of venous thromboembolism in patients with cancer: What news from clinical trials? (2018) (2)
Are placebo‐controlled trials ethical in areas where current guidelines recommend therapy? No (2006) (2)
Thrombophilic abnormalities in recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment (2006) (1)
Low-Molecular-Weight and Unfractionated Heparin for Prevention of Venous Thromboembolism in Neurosurgery (2016) (1)
Efficacy and safety of two heparin regimens for prevention of venous thromboembolism in hospitalized patients with COVID-19: a meta-analysis (2022) (1)
New strategies for enhancing the speed and rate of coronary reperfusion. (1993) (1)
Contemporary clinical management of acute pulmonary embolism: the COPE study (2022) (1)
ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis (2022) (1)
207: A Clinical Outcome-Based Prospective Study on Venous Thromboembolism in Urological Cancer Surgery: The @Ristos Project (2005) (1)
Type 2 Valvular Heart Disease Affects Decision Making for Anticoagulation in Patients with Atrial Fibrillation: The UMBRIA-Fibrillazione Atriale Prospective Study (2019) (1)
Claims-based or clinical models for predicting 90-day post-pulmonary embolism outcomes (2017) (1)
Reply to Letter: "A Randomized Study on 1-Week Versus 4-Week Prophylaxis for Venous Thromboembolism After Laparoscopic Surgery for Colorectal Cancer". (2015) (1)
Advances in Basic, Laboratory and Clinical Aspects of Thromboembolic Diseases* PREVENTION OF VENOUS THROMBOEMBOLISM IN HIGH RISK PATIENTS (1997) (1)
455Prediction of major bleeding in patients receiving DOACs for venous thromboembolism: a prospective cohort study (2019) (1)
Plasma thrombin neutralization assay (PTNA): A sensitive method to detect heparin in plasma (1992) (1)
Effect of unfractionated heparin and a low molecular weight heparin on clot sensitivity to tPA-induced lysis (1992) (1)
Thrombolytic Therapy ACCP Conference on Antithrombotic and Thromboembolic Disease : The Seventh Antithrombotic Therapy for Venous (2004) (1)
Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis after Laparoscopic Surgery for Colorectal Cancer. the PRO-LAPS II Study (2021) (1)
Defining the role of computed tomographic pulmonary angiography in suspected pulmonary embolism. (2005) (1)
Diagnosis and Treatment of Deep Vein Thrombosis in the Emergency Department: Results of an Italian Nominal Group Technique Study (2020) (1)
The protein S thrombin-sensitive region modulates phospholipid binding and the c-carboxyglutamic acid-rich (Gla) domain conformation in a non-specific manner (2006) (1)
Abstract 2394: What is the Optimal Pharmacological Prophylaxis for the Prevention of Deep-Vein Thrombosis and Pulmonary Embolism in Patients with Acute Ischemic Stroke? (2006) (1)
Incidence of Recurrent Venous Thromboembolism According to Duration of Vitamin K Antagonists: Results of a Meta-Analysis on Individual Data. (2004) (1)
Readmittance To Hospital Within 6 Months After A Venous Thromboembolism Event: Prefer In Vte Registry. (2014) (1)
Long-Term Central Vein Catheters and Venous Thromboembolism in Cancer Patients (2007) (1)
Acute pulmonary embolism: external validation of the 2014 risk stratification model of the European Society of Cardiology (2015) (1)
37 Synergistic effect of dDAVP and heparin on the increase in circulating t-PA (1988) (1)
MDCT-detected embolic burden and clinical outcome in patients with acute pulmonary embolism (2011) (1)
Clinical audit of the use of fresh frozen plasma in Umbria: study design and results of the pilot phase. (2008) (1)
Upper extremities deep vein thrombosis and DOAC treatment: a prospective cohort study (2020) (1)
Prediction of venous thromboembolism in ambulatory patients with cancer receiving chemotherapy: An expanded thromboembolic risk score model. (2011) (1)
Long-term risk of major bleeding after discontinuing anticoagulation for unprovoked venous thromboembolism: a systematic review and meta-analysis (2021) (1)
Management of heavy menstrual bleeding during direct oral anticoagulant therapy for recurrent venous thromboembolism: a case report. (2018) (1)
Data on the use of oral anticoagulants in nonagenarians with atrial fibrillation (2019) (1)
P2889The economic burden attributable to atrial fibrillation in nine European countries: perspectives from the GARFIELD-AF registry (2018) (1)
Book: Handbook on Cerebral Venous Thrombosis (2008) (1)
Risk of death in patients with major bleedings while on treatment with oral anticoagulants. (2017) (1)
NON-ANTICOAGULANT ACTIONS OF GLYCOSAMINOGLYCANS Protein Binding Studies (1996) (1)
Antimetastatic Activity of a Stable Prostacyclin Analogue: Effect on Platelet Aggregation and Host Immunocompetence in the Mouse (1991) (1)
Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study (2018) (1)
Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism. (2023) (1)
Is there still a place for thrombolytic therapy in hemodynamically stable patients with acute pulmonary embolism? No (2015) (1)
Independent Risk Factors of Catheter-Related Thrombosis (CRT) in Adult Cancer Patients: An Individual Patient-Level Data (IPD) Meta-Analysis of Randomized Clinical Trials and Prospective Cohort Studies (2008) (1)
The year in cardiology 2016: peripheral circulation (2017) (1)
Learning in times of stress: Lessons from COVID-19 that will last throughout this century (2021) (1)
Unresolved issues in the prevention and treatment of venous thromboembolism. (2002) (1)
[Determinants of prognosis in acute pulmonary embolism: the role of serum troponins]. (2008) (1)
PO-90 Clinical characteristics of cancer associated acute venous thromboembolism: findings from the MASTER Registry (2007) (1)
EFFECT OF DISTRESS ON FACTOR-VIII ACTIVITY (1977) (1)
One-week versus four-week heparin prophylaxis after laparoscopic surgery for colorectal cancer. The pro-laps pilot feasibility study (2012) (1)
Thromboembolic Complications in Covid-19: From Clinical Scenario to Laboratory Evidence (2021) (1)
Clinical significance of non clinical end-points in studies on the prevention of venous thromboembolism. (1999) (1)
Secondary Stroke Prevention in Women (2011) (1)
Contents Vol. 61, 2009 (2009) (0)
Multidetector computed tomography to assess clinical outcome in hemodynamically stable patients with acute pulmonary embolism (2009) (0)
In-hospital clinical course of patients without CK elevation following thrombolysis for ST elevation myocardial infarction: insights from the Assent-2 trial (2000) (0)
Ultrasonographic Approach for Triage of Patients With Suspected Pulmonary Embolism (1998) (0)
LOW-DOSE ASPIRIN FOR SECONDARY PROPHYLAXIS OF VEIN THROMBOSIS (THE ASPIRE STUDY) - BASELINE CHARACTERISTICS AND EVENT RATES FROM THE FIRST 380 PATIENTS (2007) (0)
Burden Of Illness Of Pulmonary Embolism In Europe – Healthcare Resource Utilization And Productivity Loss (2017) (0)
Prevalence and impact on clinical uotcome of concomitant peripheral arterial disease in patients with coronary and cerebrovascular symptoms: the PATHOS study (2003) (0)
Reply to Letter: "A Randomized Study on 1-week Versus 4-week Prophylaxis for Venous Thromboembolism After Laparoscopic Surgery for Colorectal Cancer". (2015) (0)
A survey on the views and attitudes of Italian physicians with regards to venous thromboembolism prophylaxis and treatment. (2019) (0)
Obituary JW ten Cate. (2021) (0)
Real-life use of non-vitamin K antagonist oral anticoagulants in comparison with vitamin K antagonists for non-valvular atrial fibrillation: data from a prospective cohort (2015) (0)
Deep vein thrombosis and duplex ultrasound. (1990) (0)
[Current applications and perspectives of thrombolytic therapy in peripheral arterial diseases and deep venous thrombosis]. (1995) (0)
P2246Effectiveness and safety of oral anticoagulants in patients aged 90 years or older with atrial fibrillation (2018) (0)
C0472: Trends in Medical Management of Patients with VTE in 7 European Countries: First Baseline Data of the Prefer in VTE Registry (2014) (0)
Foreword: contemporary issues in the management and treatment of atrial fibrillation (2005) (0)
RECOMMENDED ARTICLE OF THE MONTH Comment on "Fibrinolysis for patients with intermediate-risk pulmonary embolism" (2015) (0)
Front & Back Matter (2012) (0)
A survey on the views and attitudes of Italian physicians regarding the prophylaxis and treatment of venous thromboembolism (2020) (0)
Contents, Vol. 23, 1979 (1979) (0)
Title Page / Table of Contents, Vol. 26, Supplement 2, 1996 (1996) (0)
[Heparin in anesthesia. Pharmacological and clinical aspects in the prophylaxis of venous thromboembolism]. (1999) (0)
PROSPECTIVE ASSESSMENT OF CLINICAL ENDPOINTS OF VKA TREATMENT IN A PRIMARY CARE COMPUTER ASSISTED MANAGEMENT MODEL (2007) (0)
570 FRAILTY AND DISABILITY IN OLDER PATIENTS AND THE EFFECTS OF APIXABAN ON QUALITY OF LIFE AND DEPRESSIVE SYMPTOMS. THE EXPERIENCE OF THE APULEIO STUDY (2022) (0)
Subject Index Vol. 61, 2009 (2009) (0)
Therapeutic aspects of pulmonary embolism (2004) (0)
Front & Back Matter (2012) (0)
Thrombolytic therapy for acute ischaemic stroke in octogenarians: selection by magnetic resonance imaging improves safety but does not improve outcome. Editorial Commentary (2007) (0)
Complications of chronic venous access devices in cancer patients. (2003) (0)
Front & Back Matter (2012) (0)
Intravenous tissue plasminogen activator for acute stroke patients aged older than 80 years in Italy (2006) (0)
[Deep vein thrombosis: present and future drugs]. (1999) (0)
Ultrasound assessment of extravascular lung water after thoracic surgery (2015) (0)
Pharmacokinetics of the reformulated B-domain deleted recombinant factor VIII concentrate using chromogenicand one-stage assays with pooled normal plasma and refacto laboratory standard (2007) (0)
Thrombophilic abnormalities in recurrence of venous thromboembolism (VTE) in patients treated with standardized anticoagulant treatment (2006) (0)
Front & Back Matter (2012) (0)
Front & Back Matter (2012) (0)
Correction: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study [Thrombosis Journal, 16, (2018) (9)] DOI: 10.1186/s12959-018-0163-7 (2018) (0)
Acute Pulmonary Embolism and Cancer: Clinical Features, Management and Short-Term Course. Findings from the COPE Study (2022) (0)
Session 6: Heparins and fibrinolysis34 Failure of therapeutic doses of standard heparin to enhance t-PA induced thrombolysis in rabbits (1988) (0)
Risk Scores for Death in Patients with Cancer-related Venous Thromboembolism: Still a Long Road Ahead (2021) (0)
[Effect of platelet-derived growth factor on the in vitro cell proliferation of chick embryo skin]. (1983) (0)
Response to Letter by Guedes and Ferro (2008) (0)
Subject Index Vol. 35, 2006 (2006) (0)
Enhancement of endogenous fibrinolysis upon subcutaneous administration of DDAVP and heparin (1993) (0)
Front & Back Matter (2014) (0)
The additive effect of dermatan sulfate and low molecular weight heparins on thrombin inhibition in vitro (1992) (0)
Semuloparin reduced venous thromboembolism in patients receiving chemotherapy for cancer (2012) (0)
Giancarlo Agnelli Prevention of Venous Thromboembolism in Surgical Patients (2004) (0)
Book Review Thrombosis in Clinical Practice Edited by Andrew D. Blann, Gregory Y.H. Lip, and Alexander G.G. Turpie. 326 pp., illustrated. Abingdon, England, Informa Healthcare/Taylor & Francis, 2005. $139.95. 1-84214-163-5 (2006) (0)
Prognostic role of different findings at echocardiography in acute pulmonary embolism: a critical review and meta-analysis (2022) (0)
External Validation of an Integrated Risk Stratifi cation Model (2015) (0)
Front & Back Matter (2014) (0)
Risk of cerebral haemorrhage in patients treated with antithrombotic drugs. Focus on new oral anticoaguants (2011) (0)
Antithrombotic Cancer Associated Thrombosis: It May Change (2018) (0)
Low-molecular-weight heparin alone and with IIb/IIIa inhibitors in patients with renal failure and non-ST elevation acute coronary syndromes: Insights from the global registry of acute coronary events (2003) (0)
BETA-LACTAM ANTIBIOTICS AND VITAMIN K. REPLY (1992) (0)
Prospects for the prevention and treatment of venous thromboembolism (2004) (0)
Thrombolytic and haemorrhagic effects of bolus doses of rt-PA and A hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935) (1992) (0)
WEB BASED SUPPORT FOR HAEMOPHILIA MANAGEMENT: AN INTER-REGIONAL NETWORK IN MIDDLE ITALY. (2008) (0)
Editorial (Thematic Issue: Antithrombotic Therapy: Current and Future Clinical Use) (2014) (0)
Cost‐of‐Illness Analysis of Long‐Term Health Care Resource Use and Disease Burden in Patients With Pulmonary Embolism: Insights From the PREFER in VTE Registry (2022) (0)
FIXED DOSE ORAL XIMELAGATRAN IS EFFICACIOUS AND WELL TOLERATED AS THROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT OR TOTAL KNEE REPLACEMENT (2003) (0)
Pharmaceutically effective combination (1989) (0)
[Therapeutic aspects and secondary prevention of deep vein thrombosis]. (1998) (0)
[Characteristics and clinical use of rivaroxaban for the treatment of atrial fibrillation and venous thromboembolism]. (2014) (0)
Anticoagulation for atrial fibrillation in patients with active cancer: Reply to the 'Letter to the Editor' from Dr. Sorigue et al. (2019) (0)
The Diagnosis of Deep Vein Thrombosis and Pulmonary Embolism (1994) (0)
Out-of-hospital prognosis after hip surgery in patients with normal venography at discharge: clinical outcome at 3 months. (1998) (0)
Apixaban for Extended Treatment of Venous Thromboembolism (2013) (0)
Risk of haemorrhagic transformation in patients with acute ischaemic stroke and AF In patients with acute ischaemic stroke (2017) (0)
Burden Of Illness Of Deep Vein Thrombosis In Europe – Mortality And Health Related Quality Of Life (2017) (0)
Author Index / Subject Index, Vol. 25, 1995 (1995) (0)
Author and Subject Index (2005) (0)
PO-40 - Real-life use of non-vitamin k antagonist oral anticoagulants in patients with cancer associated venous thromboembolism: data from a prospective cohort. (2016) (0)
[Current role of phlebography for the diagnosis of deep venous thrombosis]. (1999) (0)
1684P Cardiovascular events with immune checkpoint inhibitors in melanoma or NSCLC: A systematic review and meta-analysis (2021) (0)
[Waiting for the new oral anticoagulants: questions and answers about dabigatran]. (2013) (0)
Incidence Of Postoperative Pulmonary Embolism (PE) Detected By Multi-slice Computerized Tomography(MSCT)In Lung Surgery For Cancer (2004) (0)
Efficacy and safety of rt-PA (Alteplase®) plus heparin vs heparin alone in pulmonary embolism (PE): PAIMS-2 results (1992) (0)
Prevalence of thrombophilic genetic mutations in patients undergoing thrombotic events while on oral anticoagulants: a case-control study (2003) (0)
Early onsetlife-threatening myelosuppression after lowdose ofintravesical thiotepa (1982) (0)
Hemorrhagic transformation in acute ischemic stroke patients and atrial fibrillation: time to initiation of anticoagulants and outcome (2018) (0)
Treatment: anticoagulation (2018) (0)
[Ten questions on the management of patients with acute pulmonary embolism]. (2018) (0)
Association between index venous thromboembolism (VTE) event and 12-months outcomes for patients in routine clinical practice enrolledin the Edoxaban Treatment in routine cliNical prActice for patients with acute VTE in Europe (ETNA-VTE-Europe) registry (2020) (0)
PO-15 Should common inherited thrombophilic abnormalities be tested in cancer patients with central venous catheter? (2007) (0)
OPTIMAL DURATION OF ANTICOAGULANT TREATMENT IN PATIENTS WITH VENOUS THROMBOEMBOLISM (2007) (0)
Front & Back Matter (2012) (0)
I Ntracerebral Hemorrhage (ich) Accounts for 10% to 15% of All Stroke Events in Western Populations. Thirty- Day Case Fatality Rates Still Range from 40% to 50% in Most Studies (0)
Letter 3: Meta‐analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery (Br J Surg 2005; 92: 1335‐1344) (2006) (0)
DESMOPRESSIN AND HAEMOSTASIS IN CHRONIC LIVER DISEASE (1988) (0)
[Occult temporal arteritis. Case reports and review of the literature]. (1982) (0)
Time course of recurrent venous thromboembolic and major bleeding events during anticoagulant therapy with apixaban or enoxaparin/warfarin: analysis of the amplify data using landmark method (2014) (0)
Abstract 19998: Event Rate in Patients with Atrial Fibrillation who Discontinue Oral Anticoagulant Therapy Early: Results from the GARFIELD Registry (2014) (0)
F-042LUNG ULTRASOUND FOR THE EVALUATION OF EXTRAVASCULAR LUNG WATER AFTER THORACIC SURGERY (2014) (0)
[Ten questions on venous thromboembolism]. (2019) (0)
Front & Back Matter (2012) (0)
Khorana risk score and PROTECHT risk score as prediction models of venous thromboembolism in cancer outpatients receiving chemotherapy: a retrospective analysis (2012) (0)
Forthcoming articles in the june issue (2005) (0)
Antithrombotic therapy for venous thromboembolic disease. (2001) (0)
Direct Oral Anticoagulants in Old and Frail Patients with Atrial Fibrillation: The Advantages of an Anticoagulation Service (2022) (0)
[Prevention of venous thromboembolism in orthopedic surgery and traumatology]. (2007) (0)
Contents Vol. 34, 2012 (2012) (0)
O1065 XIMELAGATRAN, AND ITS SUBCUTANEOUS FORM MELAGATRAN, VS. ENOXAPARIN AS THROMBOPROPHYLAXIS IN TOTAL HIP OR TOTAL KNEE REPLACEMENT (2004) (0)
P4603The burden of atrial fibrillation in the more populated European countries: perspectives from the GARFIELD-AF registry (2017) (0)
Oral Apixaban for the Treatment of Acute Venous Thromboembolism (2014) (0)
Workshop II: The future of prolonged thromboprophylaxis. (1999) (0)
Anticoagulation Management - Time to Change?: ICT Ximelagatran Satellite Symposium, Ljubljana, June 2004 (2005) (0)
Logistics of Monitoring of Vitamin K Antagonists in Western European Countries: Prefer in Vte Registry. (2014) (0)
Burden Of Illness Of Deep-Vein Thrombosis In Europe – Healthcare Resource Utilization And Productivity Loss (2017) (0)
Introduction (2005) (0)
Subject Index, Vol. 23, 1979 (1979) (0)
Thrombolysis in submassive pulmonary embolism (2004) (0)
C0473: Prevention of Thromboembolic Events? European Registry in Venous Thromboembolism - Design of the Prefer in VTE (2014) (0)
P6285Predictors of major bleeding in patients aged 90 years or over with atrial fibrillation on anticoagulant treatment (2018) (0)
Use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life: comparison with phase III trials (2015) (0)
Prevalence of unexpected pulmonary embolism at CT scan for cancer staging in patients with lung cancer (2012) (0)
EFFECTS OF STANDARD HEPARIN AND A LOW MOLECULAR WEIGHT HEPARIN (KABI 2165) ON PLASMA LEVEL OF t-PA AND PA INHIBITOR (1987) (0)
[Spinal anesthesia and prophylaxis of venous thromboembolism. Results of a national survey]. (1992) (0)
Post-discharge deep-vein thrombosis after orthopaedic surgery (1996) (0)
Duration of Anticoagulant Treatment after VenousThromboembolism (2003) (0)
PCV42 ANTICOAGULATION CONTROL IN DIFFERENT SETTINGS OF CARE: PERCEPTION, DIRECT NON-HEALTH CARE COSTS AND PRODUCTIVITY LOSSES AMONGST PATIENTS WITH ATRIAL FIBRILLATION IN AN ITALIAN REGION (2007) (0)
THE EXPRESS STUDY: PRELIMINARY RESULTS (2003) (0)
Catheter-related central venous thrombosis: The development of an Italian nationwide Consensus Paper (2007) (0)
Anticoagulation management - Time to change? Introduction (2005) (0)
Kinetics of plasma thrombin neutralizing activity in patients with deep vein thrombosis treated with subcutaneous heparin twice a day (1992) (0)
Contents Vol. 33 (2003) (0)
Spotlight: Giancarlo Agnelli, MD. Interview by Emma Baines. (2007) (0)
Interaction between thrombolytic and antithrombotic therapy in animal models (1993) (0)
Sex-differences in clinical characteristics and outcome in primary intracerebral haemorrhage (2019) (0)
Intestinal failure associated liver disease after weaning off home parenteral nutrition: a 12-month follow up (2021) (0)
P3850Impact of sex and risk factors for venous thromboembolism on the clinical course of first acute venous thromboembolism. Insights from the PREFER in VTE (2019) (0)
The Comparison of EQ-5D-5L Versus Disease/Treatment-Specific Measures in Pulmonary Embolism and Deep Vein Thrombosis (2017) (0)
GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide (2022) (0)
DOACs in patients with brain cancers: promising but still a long way to go (2022) (0)
Global Prospective Cohort Study of Factors Associated with Venous Thromboembolism in Patients with Lung Cancer Receiving Cancer Therapy (2016) (0)
JAMA Peer Reviewers for 2003 (2017) (0)
The Economic Burden of Pulmonary Embolism in Europe (2016) (0)
Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain (2022) (0)
State of the Art Lectures (2006) (0)
Inhibition of fluid phase and clot-bound thrombin by the thrombin exosite I ligand LU 58463: comparison with heparin and hirudin. (2002) (0)
Obesity and the Risk of Intracerebral Hemorrhage (0)
Inhibition of fluid phase and fibrin bound thrombin: effect of heparin, r-hirudin, PEG-rm-hirudin and a thrombin exosite inhibitor (2000) (0)
Ultra-low-molecular-weight Heparin (ULMWH) Semuloparin for Prevention of Venous Thromboembolism (VIE) in Cancer Patients Receiving Chemotherapy: Consistent Beneficial Effect Across Cancer Stage and Location Subgroups (2011) (0)
P4621Patients with cancer and atrial fibrillation treated with NOACs: data from a prospective cohort (2017) (0)
Paraneoplastic Thrombocytosis in Ovarian Cancer (2012) (0)
Despite geographical heterogeneity in baseline use, guideline-directed treatments for acute coronary syndromes improve in all regions from 1999 to 2003. The Global Registry of Acute Coronary Events (2005) (0)
Front & Back Matter (2012) (0)
Front & Back Matter (2014) (0)
Title Page / List of Contents / Preface (2012) (0)
Incidence of venous thromboembolism in patients undergoing laparoscopic surgery for colorectal cancer (2012) (0)
Observational multicenter study on effectiveness and tolerability of alirocumab in real world, The Omero study: Interim data from the fist 352 participants (2021) (0)
Venous T hromboembolism A ssociated W ith L ong-Term U se o f Central V enous C atheters i n C ancer P atients (2003) (0)
Early Time Courses of Recurrent Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer (2022) (0)
In vitro clot lysis assay. Comparison between 125I-FDP and d-dimer release (1992) (0)
Burden Of Illness Of Pulmonary Embolism In Europe – Mortality And Health Related Quality Of Life (2017) (0)
Apixaban is an Effective Replacement for Conventional Anticoagulation Therapy (2013) (0)
P5588Early versus delayed oral anticoagulation in patients with acute pulmonary embolism: determinants and outcome (2019) (0)
Contemporary Clinical Management and Course of ACUTE Pulmonary Embolism: The COPE Study (2021) (0)
Long term clinical outcomes of cancer associated venous thromboembolism: findings from the MASTER registry (2012) (0)
Management of Thrombosis in High-Risk Patients: Focus on Cancer-Associated Thrombosis (2022) (0)
Editorial: Antithrombotic therapy: current and future clinical use. (2014) (0)
Vitamin K Antagonists and Novel Oral Anticoagulant (2007) (0)
Contemporary Management and Clinical Course of Acute Pulmonary Embolism: The COPE Study (2022) (0)
P6463Prognostic value of respiratory index (RI) in hemodinamically stable patients with acute pulmonary embolism: the RI-MODEL study (2019) (0)
Combination therapy with low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE) (2003) (0)
Are recurrent ischaemic events more common in patients with aborted myocardial infarction following thrombolytic therapy? Insights from 15869 patients from the Assent-2 trial (2000) (0)
Ultraviolet spectra of membrane-rich human platelet particulates (1982) (0)
Essential pharmacology of antithrombotic agents (2014) (0)
Pooled Estimated of Effects of Anticoagulants versus Placebo or Aspirin on Hemorrhagic Stroke , Recurrent Ischemic Stroke , and Pulmonary Embolism (2007) (0)
Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial (2022) (0)
P2610Residual pulmonary obstruction and persistent right ventricular dysfunction as predictors of recurrent venous thromboembolism: a systematic review and meta-analysis (2018) (0)
Thrombolysis for the Treatment of Pulmonary Embolism (2009) (0)
Risk strati ﬁ cation and management of acute pulmonary embolism (2016) (0)
Autoimmune thyroiditis and spontaneous cervical artery dissection (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Giancarlo Dr Agnelli?

Giancarlo Dr Agnelli is affiliated with the following schools:

Giancarlo Dr Agnelli's Academic­Influence.com Rankings

Why Is Giancarlo Dr Agnelli Influential?

Giancarlo Dr Agnelli's Published Works

Published Works

What Schools Are Affiliated With Giancarlo Dr Agnelli?

Giancarlo Dr Agnelli's AcademicInfluence.com Rankings